E2F5 and cancer: In approximately half of all epithelial ovarian borderline and malignant tumours, which included serous, mucinous, endometroid and other subtypes, E2F5 expression was demonstrable by IHC, compared with none of the normal and benign cases (z = 6.1; p < 0.001; n = 135) (Table 2).